Comparing the current results to its competitors, Nevro reported Revenue decrease in the 4 quarter 2024 year on year by -9.01 %, despite the revenue increase by the most of its competitors of 8.66 %, recorded in the same quarter.
Nevro 's Comment on Competition and Industry Peers
The company operates in the spinal cord stimulation (SCS) market for chronic pain and the sacroiliac (SI) joint fusion market. Key competitors in the SCS market include Medtronic, Boston Scientific, Abbott Laboratories, Saluda, and Biotronik. In the SI joint fusion market, primary competitors are PainTeq and SI Bone. Competitive factors in these markets encompass sales force experience and access, published clinical efficacy data, product support and service, marketing and education effectiveness, brand recognition, clinical research leadership, technological innovation, product enhancements and speed of innovation, pricing and reimbursement, as well as product reliability and safety.
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Brainsway Ltd is a medical device company that focuses on developing and commercializing advanced non-invasive treatments for brain disorders. Their business model revolves around the manufacturing and sale of deep transcranial magnetic stimulation (dTMS) systems, which are used in the treatment of major depressive disorder and obsessive-compulsive disorder, among other conditions. Through partnerships with healthcare providers and licensing agreements, Brainsway aims to expand the accessibility and adoption of their innovative technologies worldwide.
Clearpoint Neuro Inc's business model revolves around providing advanced deep brain stimulation (DBS) solutions for the treatment of neurological disorders. It focuses on developing and commercializing innovative medical devices, software, and services that enable precise and accurate targeting for electrode placement during neurosurgical procedures.
Electrocore Inc operates on a business model that focuses on developing and commercializing innovative neuromodulation therapies. They utilize non-invasive vagus nerve stimulation (nVNS) to offer patients drug-free solutions for various medical conditions. The company's approach involves leveraging their understanding of the human body's electrochemical signaling system to provide targeted and effective treatments across multiple therapeutic areas.
Electromedical Technologies Inc's business model revolves around the development and commercialization of innovative medical devices. The company focuses on creating and selling safe, non-invasive therapeutic devices that utilize bioelectric technology to address various medical conditions. Through its comprehensive research, development, and marketing strategies, Electromedical Technologies Inc aims to provide effective solutions while adhering to regulatory standards in the healthcare industry.
Sources:
Nevro Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nevro Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
